The company is featured as the IBD Stock of the Day and is flashing an early buy signal as its shares break above a key short-term trendline at the 50-day moving average. Wall Street analysts, on average, recommend adding it to one's portfolio, though a note of caution is mentioned regarding the potential over-optimism of such broker recommendations, prompting a question on whether the stock is truly worth buying.